Idorsia Ltd (SWX:IDIA)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 946.67M |
| Revenue (ttm) | 220.58M |
| Net Income (ttm) | -111.70M |
| Shares Out | 251.51M |
| EPS (ttm) | -0.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,675,860 |
| Average Volume | 1,421,257 |
| Open | 3.500 |
| Previous Close | 3.764 |
| Day's Range | 3.396 - 4.100 |
| 52-Week Range | 1.152 - 4.850 |
| Beta | 1.67 |
| RSI | 57.24 |
| Earnings Date | Apr 28, 2026 |
About Idorsia
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial t... [Read more]
Financial Performance
In 2025, Idorsia's revenue was 220.58 million, an increase of 96.06% compared to the previous year's 112.51 million. Losses were -111.70 million, -57.65% less than in 2024.
Financial StatementsNews
Idorsia Q1 QUVIVIQ Revenue Improves; Reaffirms 2026 Sales Guidance
(RTTNews) - Idorsia Ltd (IDIA.SW), a commercial-stage biopharmaceutical company, announced its financial results for the first quarter of 2026, reflecting a net loss. Meanwhile, QUVIVIQ-based sales im...
Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year
Ad hoc announcement pursuant to Art. 53 LR Preparation is underway to publish the strong pediatric daridorexant data and engage with regulatory authorities on next steps Co-promotion of QUVIVIQ is bei...
Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders
Allschwil, Switzerland – April 10, 2026 Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meetin...
Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development
Allschwil, Switzerland – April 9, 2026 Idorsia Ltd (SIX: IDIA) announces the appointment of Dr Amer Joseph as Executive Vice President, Chief Medical Officer (CMO) & Head of Global Clinical Developmen...
Idorsia Transcript: Study result
A phase II study in children with insomnia, including those with neurodevelopmental disorders, showed daridorexant significantly increased sleep time and improved morning alertness with a strong safety profile. The results suggest potential benefits beyond insomnia and support further regulatory discussions for pediatric and NDD indications.
Idorsia's Daridorexant Shows Positive Phase 2 Results In Paediatric Insomnia; Stock Up
(RTTNews) - Idorsia Ltd (IDIA.SW, IDIA),a commercial-stage biopharmaceutical company,on Monday announced positive top-line results from its Phase 2 dose-finding study evaluating 10, 25, and 50 mg dose...
Idorsia announces the nomination of three candidates for election to the Board of Directors
Allschwil, Switzerland – March 24, 2026 Idorsia Ltd (SIX: IDIA) announces that the Board of Directors will propose three candidates for election to the Board at the upcoming Annual General Meeting of ...
Idorsia announces management change
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 16, 2026 Idorsia Ltd (SIX: IDIA) announces that Dr Srishti Gupta and the Board of Idorsia have mutually agreed that Srishti wi...
Idorsia expands QUVIVIQ's global footprint through new partnership with Pharmalink
Allschwil, Switzerland – March 10, 2026 Idorsia Ltd (SIX: IDIA) has entered into an exclusive agreement with Pharmalink Drug Store L.L.C for the distribution and commercialization of QUVIVIQ™ (daridor...
Idorsia Transcript: TD Cowen 46th Annual Health Care Conference
Restructured debt and strong commercial execution have positioned the company for growth, with Quviviq outperforming sales expectations and expanding globally. The pipeline advances with pivotal trials for lucerastat and new programs in dermatology and neurology, while partnership strategies aim to maximize asset value.
Idorsia Earnings Call Transcript: Q4 2025
2025 saw a turnaround with QUVIVIQ sales more than doubling and operating losses sharply reduced, driven by commercial execution and cost control. TRYVIO/JERAYGO gained regulatory traction, and the pipeline advanced with clear plans for Fabry disease and immunology assets.
Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling – further sales growth ahead with multiple pipeline catalysts in 2026
Ad hoc announcement pursuant to Art. 53 LR Idorsia delivers on its upgraded 2025 guidance, with strong QUVIVIQ sales growth, disciplined investment, and a significantly improved bottom line.
Invitation to Idorsia's FY 2025 Financial Reporting webcast and conference call
Idorsia will publish its Full Year 2025 Financial Reporting on Thursday February 26, at 07:00 CET. An investor webcast and conference call will be held to discuss the results on the same day.
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
Allschwil, Switzerland – January 30, 2026 Idorsia Ltd (SIX: IDIA) announces that the results of lucerastat treatment over 42-months and the kidney biopsy data will be presented at the 22nd Annual WORL...
Global expansion of Idorsia's QUVIVIQ continues with EMS partnership for Latin America
Ad hoc announcement pursuant to Art. 53 LR Regulatory dossier to obtain marketing authorization for QUVIVIQ has been submitted to ANVISA in Brazil Allschwil, Switzerland – January 28, 2026 Idorsia Ltd...
Idorsia Transcript: 44th Annual J.P. Morgan Healthcare Conference
Leadership outlined a focused strategy to commercialize two key assets, Quviviq and Tryvio, while advancing a robust pipeline and global expansion. Quviviq targets both nighttime and daytime insomnia symptoms, with pediatric trials and U.S. relaunch planned. Tryvio addresses resistant hypertension with strong efficacy and broad adoption potential.
Idorsia to present at J.P. Morgan 2026 Healthcare Conference
Allschwil, Switzerland – January 12, 2026 Idorsia Ltd (SIX: IDIA) announces that Srishti Gupta, MD, Chief Executive Officer of Idorsia, will present at the 44th Annual J.P. Morgan Healthcare Conferenc...
Nature Communications reports promising effect of Idorsia's lucerastat on kidney function in Fabry disease
Allschwil, Switzerland – January 12, 2026 Idorsia Ltd (SIX: IDIA) announces the publication of results from the pivotal Phase 3 MODIFY study and its open-label extension (OLE) evaluating lucerastat, a...
Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist
Allschwil, Switzerland – January 6, 2026 Idorsia Ltd (SIX: IDIA) announces the initiation of a Phase 2 proof-of-concept trial evaluating IDOR-1117-2520 for participants with moderate-to-severe psorias...
Idorsia's daridorexant in women during menopausal transition age with insomnia
Allschwil, Switzerland – January 5, 2026 Idorsia Ltd (SIX: IDIA) announces the publication of “Efficacy and safety of daridorexant for the treatment of insomnia disorder in women during menopausal tra...
Idorsia's JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension
Allschwil, Switzerland – January 5, 2026 Idorsia Ltd (SIX: IDIA) announces that Health Canada has granted marketing authorization for JERAYGO™ (aprocitentan) for the treatment of resistant hypertensio...
Idorsia's treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the ‘Best Biotechnology & Pharmaceutical Product' category
Allschwil, Switzerland – December 9, 2025 Idorsia Ltd (SIX: IDIA) announces that its novel treatment for insomnia disorder has been awarded the inaugural Prix Galien Bridges Award in the category of “...
Idorsia Transcript: Evercore ISI 8th Annual HealthCONx Conference
The company is expanding its European presence and expects to double QUVIVIQ revenues in 2025, while awaiting a US descheduling decision that could broaden access. Key pipeline assets are advancing, including a phase 1 orexin agonist and late-stage partnered programs, with several clinical milestones expected through 2026.
Idorsia's aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension
Allschwil, Switzerland – November 10, 2025 Idorsia Ltd (SIX: IDIA) announced the publication of a new analysis from the landmark Phase 3 PRECISION study in the Journal of Hypertension titled “Effects ...
Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific Sessions
Allschwil, Switzerland – November 05, 2025 Idorsia Ltd (SIX: IDIA) shares that new analysis of the landmark Phase 3 PRECISION study of aprocitentan, Idorsia's endothelin receptor antagonist, will be p...